Published in Aging and Elder Health Week, June 19th, 2005
In a recent report, researchers in Sweden conducted a study "to assess the effects of orlistat vs placebo, in combination with a weight management program, on weight loss and metabolic control in obese patients with type 2 diabetes. Patients treated with either metformin alone or metformin in combination with sulfonylurea" were randomly assigned" to double-blind treatment with orlistat or placebo (120 mg) three times daily, combined with a mildly reduced calorie diet and a weight management program for 52 weeks. Changes in body weight, anthropometry, glycemic control, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.